ArticleJCI insight2018

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Douglas B Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.